# Phase III Insulin Add-On Asia Regional Program - ST

> **NCT02096705** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 477 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin Placebo

## Key facts

- **NCT ID:** NCT02096705
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-31
- **Primary completion:** 2016-01-28
- **Final completion:** 2016-01-28
- **Target enrollment:** 477 (ACTUAL)
- **Last updated:** 2017-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02096705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02096705, "Phase III Insulin Add-On Asia Regional Program - ST". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02096705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*